Table 1. Summary of all currently... | American Society of Hematology

Table 1.

Summary of all currently reported trials of CAR-T cell therapy in T-cell malignancies

Cell source	Target	Fratricide prevention	Patients enrolled	Patients who received infusion	CR rate at day 30	Toxicity					Median follow-up	Survival		Reference
Cell source	Target	Fratricide prevention	Patients enrolled	Patients who received infusion	CR rate at day 30	CRS	ICANS	ICAHT	Infection	GVHD	Median follow-up	PFS	OS	Reference
Auto	CD7	Natural selection	65 (35 T-ALL, 25 T-LBL)	60	94%	Gd 1-2 (80.0%), Gd 3-4 (11.7%)	Gd 1 (3.3%), Gd 4 (1.7%)	Gd ≥3 (61.7%)	36.7% (any Gd), Gd 3 (16%)	3/11 (27%) mild	368.5 d	2 y 53.7%	2 y 63.5%	²¹
	CD7	PEBL	30	27	85%	Gd 1-2 (71%), Gd 3-4 (8%)	Gd 1 (7%)	Gd ≥3 (100%)	Gd 2 (8%)	Gd 2 (4%)	12 mo	1 y 22%	1 y 79%	²²
	CD7	PEBL	8 (1 T-ALL, 1 MPL, 6 T-LBL)	8	75%	Gd 1-2 (87.5%), Gd 4 (12.5%)	Nil	Any Gd (100%)	Gd 5 (12.5%)	Nil	N/A	N/A	N/A	²³
	CD7	PEBL	20∗	17	94%	Gd 1-2 (77%)	Gd 1 (12%)	Gd ≥2 (100%)	Gd 1-2 (18%), Gd 3 (29%)	N/A	15 mo	N/A	N/A	²⁴
Allo	CD7	PEBL	20	20	85%	Gd 1-2 (90%), Gd ≥3 (10%)	Gd 1-2 (15%)	Gd ≥3 (100%)	Gd 3-4 (5%), Gd 5 (20%)	Gd 1-2 (60%)	27 mo	2 y 36.8%	2 y 42.3%	²⁶
	CD7	CRISPR/Cas9 CD7 KO	28	26	52%	88.5% (any Gd), Gd ≥3 (19%)	Gd 1 (7.7%)	Neutropenia (19.2%)	Gd 3-4 (19.2%)	Gd 2 (3.8%)	N/A	N/A	N/A	²⁷
	CD7	CRISPR/Cas9 CD7 KO	12 (7 T-ALL, 4 T-LBL, 1 AML)	12	64%	Gd 1-2 (83%)	Nil	Gd 4 neutropenia (100%)	Gd 5 (8%)	Nil	10.5 mo	N/A	N/A	³⁰
	CD7	CRISPR/Cas9 CD7 KO	12 (11 T-ALL, 1 T-LBL)	12	92%	83% (any Gd), Gd 3 (67%)	Nil	N/A	Gd 5 (8%)	N/A	N/A	N/A	N/A	²⁹
	CD7	Base-editing CD7	3†	3	67%	Gd 2 (66%)	Gd 1 (33%)	Gd ≥4 (66%)	Gd 5 (33%)	Gd 2 (33%)	N/A	N/A	N/A	³¹
Auto	CD5	None	17 (TCL)	9	22%	Gd 1-2 (44%)	Gd 2 (11%)	Any Gd (56%)	Gd ≥3 (11%)	N/A	N/A	N/A	N/A	³²
Allo	CD5	CRISPR/Cas9 CD5 KO	19 (T-ALL)	16	94%	Gd 1-2 (75%)	Gd 1-2 (25%)	Gd ≥3 (100%)	Gd 3 (12%), Gd 5 (25%)	Gd 1 (69%)	14.3 mo	N/A	NR (cohort B), 4.6 mo (cohort A)	³³
Auto	TRBC1	None	12 (TCL)	12	50%	Any Gd (50%)	Nil	Gd 3-4 neutropenia (80%)	None Gd ≥3	N/A	N/A	N/A	N/A	³⁴
Allo	CD70	CRISPR/Cas9 CD70 KO	18 (TCL)	18	22%	Gd 1-2 (56%)	Gd 1-2 (17%)	N/A	Gd 1-2 (28%), Gd ≥3 (22%)	Nil	N/A	N/A	N/A	³⁵

Cell source	Target	Fratricide prevention	Patients enrolled	Patients who received infusion	CR rate at day 30	Toxicity					Median follow-up	Survival		Reference
Cell source	Target	Fratricide prevention	Patients enrolled	Patients who received infusion	CR rate at day 30	CRS	ICANS	ICAHT	Infection	GVHD	Median follow-up	PFS	OS	Reference
Auto	CD7	Natural selection	65 (35 T-ALL, 25 T-LBL)	60	94%	Gd 1-2 (80.0%), Gd 3-4 (11.7%)	Gd 1 (3.3%), Gd 4 (1.7%)	Gd ≥3 (61.7%)	36.7% (any Gd), Gd 3 (16%)	3/11 (27%) mild	368.5 d	2 y 53.7%	2 y 63.5%	²¹
	CD7	PEBL	30	27	85%	Gd 1-2 (71%), Gd 3-4 (8%)	Gd 1 (7%)	Gd ≥3 (100%)	Gd 2 (8%)	Gd 2 (4%)	12 mo	1 y 22%	1 y 79%	²²
	CD7	PEBL	8 (1 T-ALL, 1 MPL, 6 T-LBL)	8	75%	Gd 1-2 (87.5%), Gd 4 (12.5%)	Nil	Any Gd (100%)	Gd 5 (12.5%)	Nil	N/A	N/A	N/A	²³
	CD7	PEBL	20∗	17	94%	Gd 1-2 (77%)	Gd 1 (12%)	Gd ≥2 (100%)	Gd 1-2 (18%), Gd 3 (29%)	N/A	15 mo	N/A	N/A	²⁴
Allo	CD7	PEBL	20	20	85%	Gd 1-2 (90%), Gd ≥3 (10%)	Gd 1-2 (15%)	Gd ≥3 (100%)	Gd 3-4 (5%), Gd 5 (20%)	Gd 1-2 (60%)	27 mo	2 y 36.8%	2 y 42.3%	²⁶
	CD7	CRISPR/Cas9 CD7 KO	28	26	52%	88.5% (any Gd), Gd ≥3 (19%)	Gd 1 (7.7%)	Neutropenia (19.2%)	Gd 3-4 (19.2%)	Gd 2 (3.8%)	N/A	N/A	N/A	²⁷
	CD7	CRISPR/Cas9 CD7 KO	12 (7 T-ALL, 4 T-LBL, 1 AML)	12	64%	Gd 1-2 (83%)	Nil	Gd 4 neutropenia (100%)	Gd 5 (8%)	Nil	10.5 mo	N/A	N/A	³⁰
	CD7	CRISPR/Cas9 CD7 KO	12 (11 T-ALL, 1 T-LBL)	12	92%	83% (any Gd), Gd 3 (67%)	Nil	N/A	Gd 5 (8%)	N/A	N/A	N/A	N/A	²⁹
	CD7	Base-editing CD7	3†	3	67%	Gd 2 (66%)	Gd 1 (33%)	Gd ≥4 (66%)	Gd 5 (33%)	Gd 2 (33%)	N/A	N/A	N/A	³¹
Auto	CD5	None	17 (TCL)	9	22%	Gd 1-2 (44%)	Gd 2 (11%)	Any Gd (56%)	Gd ≥3 (11%)	N/A	N/A	N/A	N/A	³²
Allo	CD5	CRISPR/Cas9 CD5 KO	19 (T-ALL)	16	94%	Gd 1-2 (75%)	Gd 1-2 (25%)	Gd ≥3 (100%)	Gd 3 (12%), Gd 5 (25%)	Gd 1 (69%)	14.3 mo	N/A	NR (cohort B), 4.6 mo (cohort A)	³³
Auto	TRBC1	None	12 (TCL)	12	50%	Any Gd (50%)	Nil	Gd 3-4 neutropenia (80%)	None Gd ≥3	N/A	N/A	N/A	N/A	³⁴
Allo	CD70	CRISPR/Cas9 CD70 KO	18 (TCL)	18	22%	Gd 1-2 (56%)	Gd 1-2 (17%)	N/A	Gd 1-2 (28%), Gd ≥3 (22%)	Nil	N/A	N/A	N/A	³⁵

Allo, allogeneic; AML, acute myeloid leukemia; auto, autologous; Gd, grade; KO, knockout; MPL, mixed pjenotype leukemia; N/A, not available; NR, not reached; OS, overall survival.

∗

Only 1 of 17 enrolled in a clinical trial.

†

Only first 3 patients reported.

View Large

This Feature Is Available To Subscribers Only